Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab Optimization in Metastatic Colorectal Cancer
NCT02117466Phase 2Terminated
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2014
- Primary completion
- Jan 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in colorectal cancer (metastatic) (mCRC), sponsored by Amsterdam University Medical Center. Started Apr 2014; status: terminated.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT02117466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02117466.